OA is a chronic, progressive and disabling joint disease, leading to a poor quality of life and an enormous social and economic burden. Current therapies for OA patients remain limited, which creates an area of huge unmet medical need. For some time, researchers have been looking for approaches that can inhibit the structural progression of OA. A variety of potential disease-modifying OA drugs have been developed, targeting cartilage, inflammatory pathways or subchondral bone. In addition, non-pharmacological therapies, including joint distraction and weight loss, draw increasing attention, with some showing disease-modifying potential. Thus we performed a comprehensive review to discuss the current status of disease-modifying therapies in OA and appraise the potentials of emerging novel agents.
Introduction
OA is the most prevalent joint disorder, resulting in degradation of articular cartilage, subchondral bone remodelling and varying degrees of synovial inflammation [1] . It is associated with chronic pain, joint function impairments and disabilities, causing a poorer quality of life and significant socio-economic burden worldwide [2] . Along with the wave of aging and obesity sweeping over the world, there is an urgent need for a large increase in health services to deal with the rising epidemic of OA [3] .
However, OA is a condition that is lacking in costeffective interventions and has no cure [4] . The current treatments mainly focus on symptom relief and improvement of joint disabilities rather than modifying the disease progression. The current dilemma in OA treatment has driven investigations into new approaches to slow or reverse joint structural destruction and thus prevent the occurrence of late-stage OA and reduce the socio-economic burden. Along with an increasing knowledge of pathological processes and the development of imaging techniques and soluble biomarkers, more standardized clinical trials have been conducted and some potential diseasemodifying therapies have been discovered [57] . Some existing approaches, mainly used for symptom relief, have been further tested for their potential disease-modifying effects. A number of new agents have been developed and several have been tested in clinical trials, providing the promise of controlling the structural progression of OA by targeting cartilage metabolism and catabolism, inflammation and subchondral remodelling (Fig. 1) .
In this narrative review we discuss therapies with potential disease-modifying effects on OA, including existing treatments, as well as an update on recent developments of novel agents (Table 1) . Clinical trials of both diseasemodifying OA drugs (DMOADs) as well as non-pharmacological approaches will be appraised.
Currently available agents
Glucosamine and chondroitin sulphate Glucosamine (GS) and chondroitin sulphate (CS) have been shown to be associated with the anabolic/catabolic balance of human articular chondrocytes [8, 9] , which indicated potential disease-modifying effects of these agents. Some randomized controlled trials (RCTs) demonstrated that single use of GS or CS might have small to moderate structural protective effects in OA patients when using joint space width (JSW) or cartilage volume loss (CVL) as outcome measures [1013] . Fransen et al. [14] revealed that the JSW protection effect was achieved only in the combination use of GS and CS rather than single treatment with each of them. However, Sawitzke et al. [15] failed to find any statistically significant difference in mean JSW loss in either the single treatment group with GS or CS or the combination group. Similarly, Martel-Pelletier et al. [16] demonstrated that the combination of GS and CS did not slow the radiological deterioration of JSW in knee OA patients; instead, the combination significantly reduced CVL in some subregions.
Diacerein
Diacerein has been shown to regulate cartilage homeostasis and subchondral bone metabolism in OA by reducing the synthesis of resorptive factors (e.g. IL-1b, MMP-13 and TNF-a) as well as inhibiting the osteoclast differentiation process and the survival of mature osteoclasts [17] . Evidence to date demonstrates potential structure-modifying effects of diacerein in hip OA rather than knee OA [18] . In an RCT with hip OA patients, joint space loss was significantly reduced in the diacerein group compared with the placebo group [19] . However, because of its side effects of liver toxicity and diarrhoea, diacerein is not marketed in the USA and has been under restriction in Europe since 2014 [20] .
Hyaluronic acid
HA is responsible for several structural properties of tissues as a component of the extracellular matrix (ECM), and intra-articular injection of HA has symptomatic effects and may modify structure [21] . In an RCT, less progression of joint space narrowing (JSN) was seen in knee OA patients receiving HA with radiologically milder disease at baseline than those with radiologically more severe disease, suggesting that HA may modify joint structure at an early stage in the disease process [22] . However, a number of studies failed to find a significant structuremodifying effect of HA compared with placebo [2325] . It should be recognized that the evidence of a structuremodifying effect with these agents is insufficient and weak, thus more high-quality studies are needed to explore their roles as potential DMOADs in OA.
Therapies for regulating cartilage catabolism and anabolism
Cartilage protease inhibitors
As the main components of articular cartilage, cartilagespecific type II collagen and aggrecan are essential in maintaining the normal structure and function of joints. The proteolysis of collagen and aggrecan correlates with the progression of OA. MMPs and aggrecanase, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), are demonstrated to have emerging roles in the degradation of ECM type II collagen and aggrecan and are thus potential targets for development of OA therapies [26] .
MMPs belong to the protease superfamily of metzincins. In an interventional trial with knee OA patients, BAY 12-9566, a broad-spectrum MMP inhibitor, significantly increased the content of 846 epitopes and total type II collagen, indicating an increase in matrix synthesis of knee cartilage [27] . However, another broad-spectrum MMP inhibitor, PG116800, showed no disease-modifying effect with regards to the mean change in minimum JSW of the knee at 1 year in an RCT. The study was discontinued based on an increased frequency of musculoskeletal toxicity [28] . To avoid the musculoskeletal side effects and to increase the efficacy, recent investigational studies have assessed selective MMP inhibitors, including doxycycline, a tetracycline antibiotic. An RCT showed that doxycycline reduced the mean rate of JSN at 16 months by 40% and at 30 months by 33% among obese women with knee OA [29] . However, a Cochrane systematic review argued that doxycycline should not be applied to the treatment of knee or hip OA, due to minimal to non-existent symptomatic benefit and questionable structural benefit, as well as higher rates of adverse reactions [30] . MMP-13 is only expressed in the cartilage of OA patients, not in normal adult cartilage [31], thus selective MMP-13 inhibitors may offer new hope for the treatment of OA. Several MMP-13 inhibitors (e.g. ALS 1-0635, PF152) have shown benefits in slowing disease progression in preclinical trials; however, new selective MMP-13 inhibitors are still under development and the clinical trials remain limited [3234] . Further exploration of the specific enzymes related to musculoskeletal toxicity will generate highly selective MMP inhibitors with fewer side effects [35] .
ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) are two key aggrecanases from the ADAMTS family that are involved in cartilage degradation. Both play roles in the cleaving of the Glu373Ala374 bond in the interglobular domain of aggrecan in humans. ADAMTS-4 has also been demonstrated to cleave other CS proteoglycans and cartilage oligomeric matrix protein (COMP), as well as fibromodulin and decorin [36, 37] . Therefore, agents aimed at preventing aggrecan proteolysis by inhibiting aggrecanase activity may slow the progressive cartilage erosion and thereby act as potential DMOADs in the treatment of OA. Several small molecular aggrecanase inhibitors have been developed and were proven to be chondroprotective in models of OA [38, 39] . AGG-523 [40] , a selective oral inhibitor of ADAMTS-4 and ADAMTS-5, was the only aggrecanase inhibitor entering into phase 1 studies in humans (NCT00454298, NCT00427687), but the trials were suspended for unknown reasons. CRB0017, a chimeric murine/human IgG4 mAb against ADAMTS-5, is under preclinical development and has been proven to have beneficial structural effects in animal models of OA [41, 42] . These results pave the way for future clinical trials in OA patients.
Growth factors
Several growth factors, including fibroblast growth factor 18 (FGF-18) and bone morphogenetic protein-7 (BMP-7), have been demonstrated to stimulate cartilage anabolism and promote cartilage repair in in vitro and animal models [4345] . They pave the way for clinical investigations to further explore the potential of growth factors in cartilage regeneration in human OA.
Sprifermin, a synthetic form of human FGF-18, has exhibited potential disease-modifying effects in OA. In an RCT, intra-articular sprifermin was proven to have no statistically significant effect on the structural primary endpoint of quantitatively MRI-defined central medial tibiofemoral compartment cartilage thickness. However, it was associated with statistically significant dose-dependent reductions in JSW narrowing and loss of total and lateral tibiofemoral cartilage thickness. In addition, sprifermin was proven to be safe, with serious adverse events similar to those in the placebo group [46] . Dahlberg et al. [47] conducted a study of intra-articular sprifermin in patients with advanced knee OA. They showed that with increasing doses of up to 300 mg of sprifermin, no significant changes in cartilage parameters [bone marrow lesions (BMLs), synovitis, effusion and JSW] as measured by MRI or X-ray were reported. The lack of effect may be due to the short observation period and the small sample size. Overall, no local or systemic safety concerns were raised. A recent published study revealed that sprifermin slowed down cartilage damage from baseline to 12 months in the patellofemoral compartments and improved BMLs from 6 to 12 months for wholeknee analyses in knee OA patients, suggesting a structure protective effect of sprifermin [48] .
A member of the TGF-b family, BMP-7 (also known as osteogenic protein-1), an anabolic growth factor, has the clinical potential to repair cartilage by regulating the proliferation and differentiation of chondrocytes as well as synthesis of ECM [49] . Preclinical data have shown effects of intra-articular recombinant human BMP-7 on both joint pain alleviation and cartilage repair. A phase 1 study (NCT01111045) of intra-articular recombinant BMP-7 (eptotermin alfa) for knee OA demonstrated symptom improvement with no dose-limiting toxicity [50] . The phase 2 trial (NCT01111045) has been completed, but the results are not yet available.
Mesenchymal stem cells (MSCs)
With the potential of multidirectional differentiation, MSCs provide a promising therapeutic alternative for OA. Intraarticular injection of MSCs for the treatment of OA has suggested positive results with respect to symptom improvement and drug tolerance [5153] . Meanwhile, MSCs have shown potential effects on cartilage repair and regeneration. In a 1 year RCT, knee OA patients who received intra-articular injections of allogeneic bone marrow MSCs had a decrease in their poor-quality cartilage areas as well as an improvement in cartilage quality in these areas measured by MRI T2 mapping [52] . A proofof-concept clinical trial demonstrated that intra-articular injection of autologous adipose MSCs reduced cartilage defects in the medial femoral and tibial condyles as well as in the lateral femoral and tibial condyles and increased cartilage volume in the medial femoral and tibial condyles at 6 months [51] . However, current evidence is insufficient and there are no good data in relation to their true effects. Hence, further studies are needed to support their use as DMOADs, especially given the heterogeneity of trials to date with non-standardized ex vivo preparations of MSCs, cell doses and number of injections given.
Platelet-rich plasma
Platelet-rich plasma (PRP) contains several growth factors, including TGF-b and PDGF, VEGF, hepatocyte growth factor and FGF, which stimulate MSC proliferation and synthesis of ECM and collagen. PRP plays a potential role in OA repair partially due to the effects of these growth factors [54] . Several RCTs have shown that intraarticular injections of PRP result in no serious adverse effects and play a role in pain reduction in OA patients. But given the low to moderate methodological quality and discrepancies between studies, no definitive conclusions can be given regarding the effects of PRP in OA [55] . Presently there are still no RCTs investigating the structural effects of PRP in OA.
Cathepsin K inhibitor
Cathepsin K (CatK), a cysteine protease secreted by osteoclasts, is involved in cartilage and bone degradation [56] . Its inhibition has shown a structural protective effect in animal models [57, 58] . However, balicatib, a CatK inhibitor, has failed to decrease CVL in knee OA patients [59] . Morphea-like skin reactions have been reported in patients treated with balicatib, which were likely doserelated adverse effects and may represent a class effect of CatK inhibitors [60] . MIV-711, a highly selective CatK inhibitor, was measured in an RCT in healthy subjects [61] . It decreased biomarkers of bone resorption and cartilage degradation, including serum carboxy-terminal collagen cross links (CTX)-I levels and urinary levels of CTX-II, CTX-I and amino-terminal collagen cross links (NTX)-I, promoting further clinical trials in OA. In addition, it was proved to be safe and well tolerated. A phase 2 study (NCT03037489) of MIV-711 is in progress. By the time this article is published in early 2018, the data from the phase 2a trial may be available.
Wnt signalling pathway inhibitors
The Wnt signalling pathway is associated with joint development and the formation of bone, cartilage and synovium and has drawn increasing attention in OA research. Recent evidence from animal experiments and clinical samples showed that aberrations in Wnt signalling might be involved in OA [62, 63] . Inhibitors targeting the Wnt signalling pathway provide a new potential therapeutic strategy for OA [64] . Chen et al. [65] reported that inhibition of the histone methyltransferase enhancer of zeste homologue 2 delayed OA development through the Wnt/b-catenin pathway in mice. However, it is still a challenge to find inhibitors targeting the Wnt signalling pathway to treat human OA, thus further research is needed to fully examine the effects of Wnt signalling on OA.
Therapies for controlling inflammation
Licofelone Licofelone is a novel analgesic and anti-inflammatory agent for OA, by inhibiting both cyclooxygenase (COX) and 5-lipooxygenase [66] . It has been shown that licofelone reduces structural changes in OA by its inhibition of leucotriene-B4 and IL-1b synthesis in the synovium [67] . Licofelone also decreased both mRNA expression and protein synthesis of proteolytic enzymes involved in the degradation of cartilage, including MMP-13, CatK, ADAMTS-4 and ADAMTS-5 [68] . In a phase 3 trial, licofelone markedly reduced knee cartilage volume loss assessed by MRI over 12 and 24 months, indicating a protective effect on patients with knee OA [69] . However, more studies need to be conducted before it can be used as a disease-modifying drug in OA.
Celecoxib
Celecoxib is a type of selective COX-2 inhibitor that has been widely used in OA for inflammation and pain relief. Evidence supports that celecoxib has potential diseasemodifying properties in OA by regulating a series of inflammatory mediators, including prostaglandin E2 and inducible nitric oxide synthase (iNOS) [70] . Celecoxib prevented glycosaminoglycan release and induced proteoglycan synthesis in healthy human articular cartilage explants under the influence of blood mononuclear cells from RA patients or IL-1b and TNF-a [71] . An observational study showed a chondroprotective effect in patients with end-stage knee OA [72] . However, in an open-label pilot study, celecoxib did not provide any protective effect on CVL in knee OA patients after 12 months [73] . In general, clinical studies of celecoxib in slowing OA disease progression are scarce; more studies, particularly high-quality RCTs with large numbers of patients and long durations, are needed.
Inhibitors of pro-inflammatory cytokines
IL-1b and TNF-a are two major pro-inflammatory cytokines involved in the pathogenesis of OA [74, 75] . Inhibition of these has led to chondroprotective effects both in vitro and in animal studies [7678] . Hence it is a potential way to control structural progression of OA by regulating IL-1b and TNF-a.
Various treatment strategies could be used for specific inhibition of IL-1b production or activity, such as the application of IL-1 receptor antagonist (IL-1Ra), soluble IL-1R and mAb against IL-1b or against IL-1R1 [79] . A pilot study examined the safety and symptom relief effect of intraarticular injections of anakinra (a recombinant human IL-1Ra) in knee OA patients [80] , with pain improved by À20.4 mm (P = 0.008) and WOMAC global score by À19.5 (P = 0.005) after 3 months in those who received 150 mg IL-1Ra. In contrast, another RCT demonstrated that anakinra was not associated with improvements in OA symptoms compared with placebo [81] . Similarly, AMG 108, a fully human mAb against IL-1R1, also had no significant effect on pain reduction compared with placebo in an RCT with knee OA patients [82] . However, the effect on joint structure was not assessed in these studies. In addition, phase 2 clinical trials of the other two IL-b agents, gevokizumab (NCT01683396) and ABT 981 (NCT02087904), have been completed with no published results.
Evidence indicated a possible effect of TNF-a inhibitors in slowing the progression in hand OA. An RCT demonstrated that adalimumab significantly slowed erosive evolution compared with the placebo group in IP joints with palpable soft tissue swelling, suggesting that adalimumab halted the progression of joint damage in this subgroup [83] . In another study, infliximab was shown to reduce the anatomical lesion radiological score, thus signifying a possible disease-modifying effect on erosive hand OA [84] . However, current evidence is limited and controversial, as it did not achieve structural modification in recent trials [83, 85, 86] .
Inhibitors of iNOS
iNOS, which is highly expressed in OA cartilage, can lead to cartilage matrix and synovial tissue damage in OA by producing NO and its by-products [54] . Preclinical studies have shown that inhibition of iNOS has the potential to attenuate the disease progression of OA [87] . However, a phase 2/3 study (NCT00565821) of a selective oral iNOS inhibitor, cindunistat (SD-6010), did not slow the rate of JSN vs placebo in patients with symptomatic OA over a 2 year period [88] . Hence, further work is needed to demonstrate the efficacy of iNOS inhibitor in slowing OA progression.
GM-CSF antibody
As an inflammatory mediator, GM-CSF causes the increased production of pro-inflammatory cytokines, chemokines and proteases and thereby ultimately leads to articular cartilage destruction. Cook et al. [89] revealed that GM-CSF was essential for the development of experimental OA and its associated pain. Conversely, GM-CSF neutralization by a mAb could completely abolish existing arthritic pain and significantly reduce cartilage damage. Thus it is worthwhile to explore the clinical effect of GM-CSF antibody in OA. Currently a phase 2 clinical study (NCT02683785) is under way to investigate the effectiveness and safety of GSK3196165 (a fully human Human Combinatorial Antibody Library antibody directed against GM-CSF) in patients with inflammatory hand OA.
Therapies for remodelling subchondral bone

Strontium ranelate
Strontium ranelate is able to dissociate the bone remodelling process and change the balance between bone resorption and formation [90] . An RCT with knee OA demonstrated that besides the beneficial effect on symptoms, treatment with strontium ranelate was associated with smaller degradations in JSW than placebo and less radiological progression was observed over 3 years [91] . In a phase 3 clinical trial in knee OA, treatment with strontium ranelate was found to have beneficial effects on structural changes by significantly reducing CVL in the plateau and BML progression in the medial compartment [92] . However, because of its potential cardiovascular risk, its use in OA needs to be further explored.
Bisphosphonates
There has been interest in the possible beneficial effects of bisphosphonates, the most widely used therapeutic agents in osteoporosis, on OA. Preclinical studies have provided evidence for bisphosphonates as a diseasemodifying agent in OA [93] . The efficacy of bisphosphonates in human OA was assessed in clinical trials with mixed results. An RCT revealed that a single infusion of i.v. zoledronic acid (5 mg) was effective in reducing knee pain and BML size after 6 months, and with a trend after 12 months, indicating that zoledronic acid may slow the progression of knee OA [94] . Similar effects were achieved with another bisphosphonate in a British phase 2 study demonstrating that risedronate resulted in improvement of symptoms and joint structure in patients with primary knee OA. An observational cohort study investigated the effect of bisphosphonate use on symptomatic and radiographic knee OA in participants from the National Institutes of Health Osteoarthritis Initiative cohort. By year 4, even though the JSW decreased linearly over time in both groups, there was a difference in JSW of 0.35 mm between the bisphosphonate users and nonusers. There was a beneficial trend on structural progression, with less JSN in the bisphosphonate users (0.51 vs 0.29 mm; P = 0.06), but it did not reach statistical difference [95] . In the Knee OA Structural Arthritis study, no symptom improvement or slowing of radiographic progression was observed in each treatment dose group (up to 50 mg/week for 2 years), although a reduction in the level of a biochemical marker of cartilage degradation was observed [96] . So far, the evidence is insufficient, but additional studies will allow for understanding of the diseasemodifying effect of bisphosphonates.
Calcitonin
Calcitonin regulates calcium homeostasis by reducing osteoclastic resorption and increasing osteoblasts activity and thus is useful for the treatment of some metabolic bone diseases [97] . Studies have shown that calcitonin attenuates cartilage degeneration and increases subchondral bone turnover [98, 99] . Two phase 3 trials (NCT00486434, NCT00704847) evaluated the structuremodifying and symptom-relieving efficacy of 2 year treatment with oral salmon calcitonin in patients with painful knee OA with structural manifestations. However, at the 24 month endpoint, there was no statistically significant effect on JSN measured by X-ray in either of the studies, although oral salmon calcitonin significantly slowed total CVL assessed by MRI in one trial [100] .
Non-pharmacological treatments
Joint distraction
Joint distraction is a joint-preserving surgery in which the two bony ends of a joint are slightly separated. An external fixation frame is generally implemented in the procedure to maintain and regulate this distance, thus alleviating the loading stress and enlarging the space of the joint [101] . It was first used in 1979, when patients with various hip diseases received joint distraction. Satisfactory results were achieved in > 70% of patients 445 years of age, including the potential effect of cartilage repair [102] . Subsequently, joint distraction was aimed at patients with ankle OA. In a 2 year follow-up trial of 17 patients with severe ankle OA, in most cases the JSW significantly increased and remained widened for 2 years as measured by mortise view radiographs. This lead to the conclusion that such structural changes were possibly due to cartilage repair after joint distraction [103] . In a proof-of-concept study, radiographic evaluation showed an increase in JSW and a decrease in subchondral sclerosis among 12 of 17 patients with severe ankle OA after an average 2.8 years of follow-up, suggesting the presence of structural changes [104] . The structural changes could also be seen in knees after joint distraction. Intema et al. [105] reported an increase in the mean and minimum JSN and cartilage thickness and a decrease in denuded bone areas at 1 year follow-up of 20 patients with knee OA. In addition, the collagen type II synthesis:breakdown ratio was increased. Similar findings were seen in another study of knee OA [106] . The potential mechanism to explain the disease-modifying effect of distraction is that the joint distraction attenuates secondary inflammation, cartilage degeneration and subchondral bone remodelling due to the absence of mechanical loading as well as improvement of joint fluid flow and an intermittent increase in intra-articular hydrostatic pressure [107] .
Despite of the encouraging results, most of the studies were relatively short term with small sample sizes and a high failure rate occurred in a considerable number of patients during follow-up [108] . Moreover, the potential complications of joint distraction should be a concern, especially the common pin tract infection [107, 109] . Thus further high-quality studies are needed to confirm its long-term efficacy and safety.
Weight loss
An increasing number of studies support the potential feasibility of weight loss (WL) for disease modification in OA. A prospective, beforeafter trial with 64 subjects who were morbidly obese showed that surgically induced WL effectively reversed the radiological signs of early changes in knee OA, with a greater increase in mean JSW [110] . Serebrakian et al. [111] reported that a reduction of 510% of body weight was associated with significantly smaller increases in cartilage T2 in the medial femoral condyle and overall medial compartment in a 48 month study, suggesting WL might attenuate cartilage matrix degeneration. A 12 month observational prospective cohort study showed that WL in obese people had structuremodifying effects on medial articular cartilage by increasing proteoglycan content and reducing cartilage thickness loss [112] . It was demonstrated that WL is associated with reduced medial tibial CVL and cartilage thickness loss, indicating a potential role of disease modification in knee joint structure [113, 114] . WL was also proven to increase procollagen type II N-terminal propeptide and adiponectin, and decrease leptin and cartilage oligomeric matrix protein (COMP) plasma concentrations, which suggested a structure-modifying effect on cartilage [115] . Conversely, some RCTs failed to demonstrate a disease-modifying effect of WL in OA. In an RCT [116] with 252 knee OA patients, a 5% WL over 18 months showed no effect on structural progression as assessed by medial and lateral JSW. Similarly, another RCT that enrolled 454 overweight and obese older adults with knee pain and radiographic evidence of tibiofemoral OA showed no influence of WL on the rate of structural progression either on X-ray or MRI over 18 months [117] .
The role of WL in the structural progression of OA remains controversial and studies have failed to reach agreement due to contrary conclusions. Further investigations are needed to verify these conclusions, taking into account both the effectiveness and tolerance of WL based on the individual's condition [118] .
Physical activity
A number of studies have shown the potential effect of physical activity (PA) in the biochemical composition of cartilage both in people at high risk of developing OA and patients with OA. A 4 month RCT demonstrated that moderate exercise improved joint symptoms and function as well as the glycosaminoglycan content of knee cartilage in patients at high risk of developing OA [119] . Likewise, it has been shown in 87 post-menopausal women with knee OA that a 12 month leisure-time PA program had a positive effect on the glycosaminoglycan content of tibiofemoral cartilage measured by delayed gadolinium-enhanced MRI [120] . In addition, Racunica et al. [121] reported vigorous PA was associated with an increase in tibial cartilage volume and a reduction in the risk of BMLs, indicating a protective effect of PA on knee cartilage. Crescuillo et al. [122] conducted a 12 month follow-up study of 486 females with symptomatic OA. The study showed that light to moderate PA at a frequency of 14 days per week appeared to lead to a slight reversal in the progression of OA or a possible slowing of OA. An RCT with 221 older knee OA patients showed that lower-extremity strength training induced less frequent progressive JSW over 30 months, indicating a disease-modifying effect of PA in knee OA [123] . In addition, an RCT demonstrated that serum COMP significantly decreased after strengthening exercises, also suggesting a potential beneficial role of PA in cartilage structure [124] .
However, extreme or improper PA poses a risk of joint injuries. High-impact PA with too much loading on joint cartilage may increase the incidence of OA [125] . Interestingly, there are recent claims that the current available evidence is insufficient to conclude that higherintensity exercise induces greater adverse effects [126] . Thus this highlights the need for more studies to determine the effects of PA in OA, with a focus on the duration, intensity and frequency of PA.
Biomechanical intervention
Knee braces can potentially slow structural disease progression in OA. In an RCT including 126 subjects 4070 years of age with knee OA, the group allocated to patellofemoral bracing had an overall BML volume 18% less than the group without the brace (P = 0.03) [127] . A metaanalysis of 17 studies (218 participants) found that valgus knee bracing significantly reduced the knee adduction moment, a biomechanical measure that has been related to structural disease progression [128] . Flat flexible shoes have also been reported to result in significantly lower parameters of knee adduction movements [129, 130] .
Nevertheless, evidence remains scarce and robust clinical trials are required to evaluate whether these interventions slow structural disease progression in OA.
Conclusion
The rationale for the development of DMOADs is strong. With current management predominantly focusing on symptom control, there is an unmet need for agents that will prevent or control the progression of OA. Some clinical trials suggest that the therapeutic value of current agents may extend beyond symptom relief to act as potential DMOADs. A number of target-specific agents are being tested, some of which have shown beneficial effects of structural modification in clinical trials. In addition, nonpharmacological treatments have attracted greater attention recently and favourable results of disease modifications have been reported. However, most trials have failed to obtain the desired results, probably due to inappropriate clinical design, insensitive outcome measures or uncontrollable side effects. All in all, OA is a complex, heterogeneous, whole-joint disease with multiple aetiologies and different phenotypes, which makes it a challenging task to develop ideal approaches. Thus more high-quality clinical trials are necessary to properly assess the effectiveness of these interventions in delaying the structural progression of OA and to provide adequate support for their application in practice. 
